Neu­ro­crine ex­ecs shrug off a PhII set­back for Tourette syn­drome

Neu­ro­crine was forced to con­cede that its lead drug – al­ready on track at the FDA with an ap­pli­ca­tion for tar­dive dysk­i­ne­sia — just flunked a Phase II tri­al in Tourette syn­drome.

The VMAT2 in­hibitor im­proved symp­toms among the pa­tients tak­ing the drug, but failed to hit the pri­ma­ry end­point for the change-from-base­line in the Yale Glob­al Tic Sever­i­ty Scale at week 8. The biotech, though, is keep­ing the hard da­ta un­der wraps for now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER